CSL Vifor 보도자료 - 뉴스와이어

기업 뉴스룸

CSL Vifor

제약

ST. GALLEN, Switzerland

CSL Vifor 보도자료

6개

RSS 이메일

2022년 12월 14일 15:40

Cancellation of remaining publicly held registered shares of Vifor Pharma AG

Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal va

건강 제약 투자

2022년 11월 28일 16:05

Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients

Regulatory News: CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients f

건강 제약 병원/의료 개발

2022년 11월 25일 15:35

Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously

Regulatory News: Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL Vifor is supporting a growing alliance of international organizations including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart

건강 제약 병원/의료 사업계획

2022년 8월 23일 16:50

CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading caus

건강 제약 개발

2022년 8월 22일 16:30

VFMCRP announces U.S. Court upholds validity of Velphoro® patent

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferr

건강 제약 소송

2022년 8월 19일 14:50

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first ther

건강 제약 병원/의료 개발